Stockreport

Aquestive Therapeutics Touts Anaphylm, Targets Q3 FDA Resubmission After CRL at Oppenheimer Conference [Yahoo! Finance]

Aquestive Therapeutics, Inc.  (AQST) 
Last aquestive therapeutics, inc. earnings: 3/11 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.aquestive.com/investor-relations
PDF plans a Q3 resubmission with a six-month review and is targeting approval in Q1 2027 while seeking an accelerated review. Anaphylm is a needle-free sublingual epinephr [Read more]